Publication | Closed Access

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

Tumor BiologyOncologyMedicineDual Mesenchymal-epithelial TransitionPathologyEpithelial-mesenchymal InteractionsBronchial NeoplasmAnti-cancer AgentCancer TreatmentCancer BiologyCell BiologyAnaplastic Lymphoma KinaseLung CancerCancer Research